EngiChem Lifesciences, under CEO Ki-Young Son, is launching full-scale development of an AI-based anti-aging drug. Using advanced software to identify small molecules targeting senescent cells, they aim to reduce discovery time and costs. With a history in anti-inflammatory and anticancer research, they plan to secure IP by early 2026. This is a promising example of AI innovation in biotechnology.